iSpecimen Inc. Net Fee Amt
iSpecimen Inc. (ISPC) had Net Fee Amt of $138.1 as of 2026-06-24, per its S-1/A filed 2026-07-17.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-17
- 2026-06-24: Net Fee Amt $138.10; Net Fee Amt as first filed $552.40.
- 2026-06-01: Net Fee Amt $216.80.
| Period end | Net Fee Amt | Net Fee Amt as first filed |
|---|---|---|
| 2026-06-24 | $138.10 S-1/A · filed 2026-07-17 | $552.40 S-1 · filed 2026-06-24 |
| 2026-06-01 | $216.80 S-3 · filed 2026-06-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |